EBR Submits TGA ARTG Application for WiSE System
Filed with ASX · · 3 pages · English
Summary by 6ix AI
EBR Systems, Inc. has submitted an application to the Therapeutic Goods Administration for the WiSE System to be included on the Australian Register of Therapeutic Goods. This submission is a significant step in the company's regulatory and commercialization strategy, following the grant of Priority Review Determination by the TGA. If approved, the WiSE System would provide Australian heart failure patients with access to a unique wireless pacing option that does not require traditional leads. The application is supported by prior FDA approval in the U.S., aiming to expand EBR's market presence beyond the U.S.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from EBR Systems
- Notification regarding unquoted securities - EBR
- EBR Systems to Participate in 19th APHRS 2026
- Amended Appointment of Chief Medical Officer
- Application for quotation of securities - EBR
- Appointment of Chief Medical Officer
Later from EBR Systems
- Notification of cessation of securities - EBR
- EBR to Present at Canaccord Genuity Forum
- Q3 2026 Quarterly Activity Report and Form 10-Q Submission
- Investor Webinar
- Investor Webinar - Updated
Follow EBR Systems into a list and get an email when it puts out news.
Follow EBR Systems